论文信息 - MYLERAN THERAPY IN BRONCHOGENIC CARCINOMA

MYLERAN THERAPY IN BRONCHOGENIC CARCINOMA

1,4-Dimethanesulfonyloxybutane (Myleran) has been reported to be effective in chronic myelogenous leukemia, but lacking antitumor activity in other types of neoplastic More recently, Sykes et aL6 observed clinical response in chronic lymphatic leukemia and malignant lymphoma. The current study was designed to investigate the effects of Myleran in bronchogenic carcinoma, using dosage schedules comparable in bone marrow depressant activity to that resulting from intravenous nitrogen mustard (HN2).

R. D. Sullivan

[1] A. Gellhorn,et al. Myleran therapy in malignant neoplastic disease; use of 1,4-dimethanesulfonyloxbutane with emphasis on chronic granulocytic leukemia. , 1956, Journal of the American Medical Association.

[2] J. W. Frost,et al. Myleran in the treatment of chronic granulocytic leukemia. , 1956, Journal of the American Medical Association.

[3] D. Karnofsky,et al. Comparative therapeutic activity of the nitrogen mustards and allied compounds. , 1956, The Medical clinics of North America.

[4] D. Galton,et al. Myleran in chronic myeloid leukaemia. , 1955, Lancet.

[5] N. Petrakis,et al. The effect of 1,4‐dimethanesulfonyloxybutane (GT‐41 or myleran) upon leukemia , 1954, Cancer.

[6] A. Haddow,et al. Myleran in chronic myeloid leukaemia; chemical constitution and biological action. , 1953, Lancet.

[7] D. Galton. Myleran in chronic myeloid leukaemia; results of treatment. , 1953, Lancet.